Home › Funds › DME Capital Management, LP › LKFT
DME Capital Management, LP position in LKFT
LAKEFRONT BIOTHERAPEUTICS NV
DME Capital Management, LP reported holding 482,746 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$14.5M, representing 0.37% of its reported portfolio and ranking #41 among its reported holdings. DME Capital Management, LP has disclosed LKFT holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DME Capital Management, LP's LKFT position evolved
DME Capital Management, LP first disclosed a stake in LKFT in Q1 2024 at 159,828 shares (US$5.1M). The position peaked in Q3 2025 at 482,746 shares, worth US$16.7M. Across 10 filings, DME Capital Management, LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 482,746 shares valued at US$14.5M. Notable position changes include a 47% increase in Q2 2024 (shares rose 16% over the following quarter), a 104% increase in Q3 2024 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 159.83K | $5.15M | New |
| Q2 2024 | 234.83K | $5.82M | Add |
| Q3 2024 | 479.36K | $13.80M | Add |
| Q4 2024 | 479.36K | $13.18M | Hold |
| Q1 2025 | 482.75K | $12.13M | Add |
| Q2 2025 | 482.75K | $13.51M | Hold |
| Q3 2025 | 482.75K | $16.72M | Hold |
| Q4 2025 | 482.75K | $15.79M | Hold |
| Q1 2026 | 482.75K | $14.48M | Hold |
| Q2 2026 | 482.75K | $14.47M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LKFT and 13F data
LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 17 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$500.2M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LKFT
- GILEAD SCIENCES, INC. 16.71M sh · $500.16M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 3.79M sh · $113.50M · Q2 2026
- Madison Avenue Partners, LP 3.45M sh · $103.37M · Q2 2026
- Prosight Management, LP 2.04M sh · $61.26M · Q2 2026
- EcoR1 Capital, LLC 1.67M sh · $49.98M · Q2 2026
- DAFNA Capital Management LLC 130.18K sh · $3.90M · Q2 2026
More on DME Capital Management, LP
FAQ
How long has DME Capital Management, LP held LKFT?
DME Capital Management, LP has disclosed LKFT holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is DME Capital Management, LP's current position in LKFT?
As of Q2 2026, DME Capital Management, LP holds 482.75K shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $14.47M, representing 0.37% of its reported portfolio and ranking #41.
Has DME Capital Management, LP been buying or selling LKFT?
In the latest 13F filing (Q2 2026), DME Capital Management, LP held unchanged its position in LKFT. The position peaked in Q3 2025 at 482.75K shares.
Which other funds hold LKFT?
Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 17 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.